SYNERGY trial
Jump to navigation
Jump to search
Introduction
Study characteristics:
- 10,0000 NSTEACS* patients
- randomized trial
- unfractionated heparin vs enoxaparin
Results:
- death or non-fatal myocardial infarction within 30 days 14% in both groups
- in hospital bleeding more more common in enoxaparin group (9% vs 8%)#
* non ST segment elevation acute coronary syndrome (NSTEACS)
More general terms
References
- ↑ Journal Watch 24(18):142, 2004 Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, Kereiakes DJ, Langer A, Mahaffey KW, Nessel CC, Armstrong PW, Avezum A, Aylward P, Becker RC, Biasucci L, Borzak S, Col J, Frey MJ, Fry E, Gulba DC, Guneri S, Gurfinkel E, Harrington R, Hochman JS, Kleiman NS, Leon MB, Lopez-Sendon JL, Pepine CJ, Ruzyllo W, Steinhubl SR, Teirstein PS, Toro-Figueroa L, White H; SYNERGY Trial Investigators. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA. 2004 Jul 7;292(1):45-54. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15238590